Payment overview · 2025
General Payments
$1,905.62
88 reported records · 25 companies
Healthcare provider profile · identity verified
Walter Klein, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Gastroenterology · HARRINGTON PARK, NJ · NPI 1821099078
Verified facts
What the public records show
CMS Open Payments records show Walter Klein, M.D. received $1,905.62 in general payments during 2025 across 88 reported records.
Janssen Biotech, Inc. accounted for 18.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Linzess by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $359.85 | 18.9% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $339.53 | 17.8% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $221.10 | 11.6% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $174.47 | 9.2% | 13 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $157.59 | 8.3% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $105.08 | 5.5% | 6 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $87.77 | 4.6% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $61.11 | 3.2% | 4 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.14 | 2.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $40.77 | 2.1% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $37.45 | 2.0% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $29.09 | 1.5% | 2 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $24.39 | 1.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.46 | 1.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $23.10 | 1.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $20.49 | 1.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $19.43 | 1.0% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $18.94 | 1.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.74 | 1.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.02 | 0.9% | 1 | 2025 |
| Resmed Corp | Unresolved — no canonical attribution shown | $16.71 | 0.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.48 | 0.9% | 1 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $16.28 | 0.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.04 | 0.8% | 1 | 2025 |
| Olympus America Inc. | Unresolved — no canonical attribution shown | $13.59 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,905.62 | 88 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $359.85 | 13 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $298.28 | 5 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $157.59 | 9 | 2025 |
Source payment records
|
|||||
| VELSIPITY Normalized: velsipity |
Drug | PFIZER INC. | $125.04 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $71.45 | 4 | 2025 |
Source payment records
|
|||||
| ENTYVIO Normalized: entyvio |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $67.83 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $61.11 | 4 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $49.43 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $47.14 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $44.24 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $40.77 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $38.95 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $37.45 | 2 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $33.43 | 2 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $33.43 | 2 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $24.39 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.46 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23.10 | 1 | 2025 |
Source payment records
|
|||||
| Padcev Normalized: padcev |
Drug | Astellas Pharma US Inc | $20.49 | 1 | 2025 |
Source payment records
|
|||||
| EOHILIA Normalized: eohilia |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| AIRSENSE Normalized: airsense |
Device | Resmed Corp | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| Kineret Normalized: kineret |
Drug | SOBI, INC | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| HANAROSTENT Esophagus TTS(CCC) Normalized: hanarostent esophagus tts ccc |
Device | Olympus America Inc. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 337 | 119 |
| Sod Sulf-Potass Sulf-Mag Sulf | Sodium, Potassium,mag Sulfates | 221 | 218 |
| Atorvastatin Calcium | Atorvastatin Calcium | 176 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 147 | 42 |
| Metformin Hcl | Metformin Hcl | 128 | 43 |
| Amlodipine Besylate | Amlodipine Besylate | 102 | 31 |
| Omeprazole | Omeprazole | 99 | 32 |
| Famotidine | Famotidine | 77 | 28 |
| Alprazolam | Alprazolam | 68 | 18 |
| Levothyroxine Sodium | Levothyroxine Sodium | 60 | 16 |
| Lisinopril | Lisinopril | 56 | 16 |
| Valsartan | Valsartan | 53 | 18 |
| Linzess | Linaclotide | 52 | suppressed |
| Losartan Potassium | Losartan Potassium | 50 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 34 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 34 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | 17 |
| Furosemide | Furosemide | 30 | suppressed |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 30 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Potassium Chloride | Potassium Chloride | 28 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Simvastatin | Simvastatin | 26 | suppressed |
| Allopurinol | Allopurinol | 25 | suppressed |
| Carvedilol | Carvedilol | 23 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Eliquis | Apixaban | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Trulance | Plecanatide | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Mesalamine | Mesalamine | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 14 |
| Diazepam | Diazepam | 13 | suppressed |
| Gabapentin | Gabapentin | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Clenpiq | Sod Picosulf/Mag Ox/Citric Ac | 11 | 11 |
| Lidocaine | Lidocaine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,905.62 · 88 records | Janssen Biotech, Inc. | ACTHAR, AIRSENSE, BREZTRI, CAPLYTA, CREON, Dexcom G6 Transmitter, ENTYVIO, EOHILIA, EVENITY, FREESTYLE LIBRE 3, GEMTESA, GVOKE HYPOPEN, HANAROSTENT Esophagus TTS(CCC), Kineret, Korlym, LINZESS, OTEZLA, Padcev, REPATHA, REXULTI, RINVOQ, SKYRIZI, TREMFYA, VELSIPITY, VIBERZI, VOQUEZNA, VRAYLAR, Wegovy, XELJANZ, ZENPEP, ZEPBOUND, ZORYVE, t:slim X2 Insulin Pump with Control-IQ | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error